GenSight Biologics S.A.
EPA:SIGHT.PA
0.39 (EUR) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | GenSight Biologics S.A. |
Symbool | SIGHT.PA |
Munteenheid | EUR |
Prijs | 0.39 |
Beurswaarde | 41,058,228 |
Dividendpercentage | 0% |
52-weken bereik | 0.282 - 0.919 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bernard Gilly Ph.D. |
Website | https://www.gensight-biologics.com |
An error occurred while fetching data.
Over GenSight Biologics S.A.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010),
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)